Travere Therapeutics, Inc. (TVTX)
66.64
+1.42
(+2.18%)
USD |
NASDAQ |
Aug 25, 10:52
Travere Therapeutics Price to Book Value : 255.92 for Aug. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 250.47 |
| August 21, 2026 | 252.35 |
| August 20, 2026 | 247.55 |
| August 19, 2026 | 253.31 |
| August 18, 2026 | 245.40 |
| August 17, 2026 | 243.98 |
| August 14, 2026 | 238.64 |
| August 13, 2026 | 235.92 |
| August 12, 2026 | 238.72 |
| August 11, 2026 | 231.23 |
| August 10, 2026 | 233.84 |
| August 07, 2026 | 235.49 |
| August 06, 2026 | 239.83 |
| August 05, 2026 | 241.02 |
| August 04, 2026 | 215.14 |
| August 03, 2026 | 211.14 |
| July 31, 2026 | 214.64 |
| July 30, 2026 | 219.98 |
| July 29, 2026 | 213.37 |
| July 28, 2026 | 214.72 |
| July 27, 2026 | 217.67 |
| July 24, 2026 | 220.28 |
| July 23, 2026 | 217.67 |
| July 22, 2026 | 216.06 |
| July 21, 2026 | 217.29 |
| Date | Value |
|---|---|
| July 20, 2026 | 213.03 |
| July 17, 2026 | 217.79 |
| July 16, 2026 | 212.30 |
| July 15, 2026 | 217.90 |
| July 14, 2026 | 219.13 |
| July 13, 2026 | 216.18 |
| July 10, 2026 | 217.33 |
| July 09, 2026 | 224.55 |
| July 08, 2026 | 224.13 |
| July 07, 2026 | 222.17 |
| July 06, 2026 | 220.75 |
| July 02, 2026 | 218.60 |
| July 01, 2026 | 216.37 |
| June 30, 2026 | 218.17 |
| June 29, 2026 | 54.57 |
| June 26, 2026 | 55.08 |
| June 25, 2026 | 55.25 |
| June 24, 2026 | 53.99 |
| June 23, 2026 | 52.37 |
| June 22, 2026 | 51.58 |
| June 18, 2026 | 51.62 |
| June 17, 2026 | 50.67 |
| June 16, 2026 | 49.96 |
| June 15, 2026 | 50.35 |
| June 12, 2026 | 48.71 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Insmed, Inc. | 36.34 |
| United Therapeutics Corp. | 3.455 |
| Krystal Biotech, Inc. | 7.634 |
| Relay Therapeutics, Inc. | 5.011 |
Price to Book Value Related Metrics
| PS Ratio | 10.66 |
| Price to Free Cash Flow | 409.24 |
| Price | 66.64 |
| Earnings Yield | -1.15% |
| Market Cap | 6.276B |